Informational only. Not medical advice.INFORMATIONAL PLATFORM ONLY — NOT MEDICAL ADVICE, DIAGNOSIS, OR TREATMENT
Informational only. Not medical advice.INFORMATIONAL PLATFORM ONLY — NOT MEDICAL ADVICE, DIAGNOSIS, OR TREATMENT
Head-to-head comparison of CDP-Choline (Citicoline) and Nefiracetam — mechanism, dosing, side effects, legal status, and pricing.
CDP-choline (citicoline) is a non-peptide cytidine nucleotide-choline conjugate that serves as an intermediate in phosphatidylcholine biosynthesis. It is approved as a prescription drug for stroke and cognitive disorders in Japan and parts of Europe but sold only as a dietary supplement ingredient in the United States, where it is not FDA-approved as a drug. Human evidence is mixed and indication-dependent: small trials report modest memory improvements in healthy/older adults, but the largest phase 3 RCT (COBRIT, n=1,213 traumatic brain injury patients) found no benefit over placebo.
Nefiracetam is a non-peptide small molecule in the racetam (pyrrolidinone/2-oxopyrrolidine acetamide) class, investigated as a cognitive enhancer. It was never approved by the FDA, EMA, or Japan's PMDA; Daiichi Seiyaku withdrew its Japanese NDA (Translon) in February 2002 after a repeat Phase III trial in dementia failed to demonstrate efficacy. A US/Canada Phase II trial in poststroke depression (600 mg and 900 mg/day) showed no overall separation from placebo, though a subgroup analysis suggested benefit in the most severely depressed patients at 900 mg. No validated therapeutic dose or approved indication exists; it is sold by research-chemical and laboratory-reagent suppliers for research use only.
CDP-Choline (Citicoline)
Nefiracetam
Category
Legal Status
Mechanism
COA-verified vendors · trust score ≥70 required · single-vial price — bulk/bundle deals may be lower
CDP-Choline (Citicoline)
No pricing data yet.
Check CDP-Choline (Citicoline) prices →Nefiracetam
No pricing data yet.
Check Nefiracetam prices →COA corpus from Disclosed Labs — independently tested batches only.
CDP-Choline (Citicoline)
No COA data yet.
Submit testing data →Nefiracetam
2
COAs
99.6%
Avg purity
2
Labs
Human evidence is mixed and indication-dependent. Small-to-moderate placebo-controlled RCTs in healthy/older adults and age-associated memory impairment report modest verbal/episodic memory improvements at ~500–1,000 mg/day over weeks to months. However, the largest trial to date—COBRIT, a phase 3 double-blind placebo-controlled RCT in 1,213 traumatic brain injury patients—found no benefit over placebo on functional or cognitive outcomes (GOS-E favorable outcome 35.4% citicoline vs 35.6% placebo; global OR 0.98, 95% CI 0.83–1.15). Evidence for Alzheimer's disease and MCI is described in reviews as insufficient and inconsistent. In preclinical models, aged rats with hippocampal damage showed reduced long-term memory impairment with dietary CDP-choline supplementation, and mice subjected to ischemic stroke showed SIRT1-dependent reduction in cerebral infarct volume.
Key references
Human clinical data are limited and largely negative or mixed. Japanese Phase II/III trials in dementia/cognitive sequelae after cerebrovascular disorders showed improvement over placebo in some early trials, but a Ministry of Health-mandated repeat Phase III trial under revised guidelines failed to demonstrate efficacy, and Daiichi Seiyaku withdrew its Japanese NDA (Translon) in February 2002. A US/Canada multicenter randomized double-blind Phase II trial (28 sites, 1999–2001, n=159) tested nefiracetam 600 mg and 900 mg/day vs. placebo for poststroke depression; the drug did not separate from placebo overall (response >70%, remission >40% in both arms) but showed significant benefit in the most-severely-depressed subgroup at 900 mg (Robinson et al., J Neuropsychiatry Clin Neurosci 2008). A related post hoc analysis examined apathy outcomes in the same cohort. Preclinical findings include: rat cortical neurons showed potentiation of native α4β2-type nicotinic acetylcholine receptor currents via a G(s)-protein-dependent pathway; rat dorsal root ganglion neurons showed dual concentration-dependent effects on GABA_A receptor-channel currents mediated via cAMP-dependent protein kinase and Gi/Go proteins; rat neuronal preparations showed enhancement of high-voltage-activated N/L-type Ca²⁺ channel currents and modulation of NMDA receptor function via PKC-dependent phosphorylation; rat passive avoidance models showed reversal of apomorphine-induced amnesia and preservation of hippocampal NCAM-mediated memory consolidation during scopolamine disruption.
CDP-Choline (Citicoline) and Nefiracetam are both in the Cognitive category and may have overlapping mechanisms. Researchers should review both profiles carefully, understand the mechanisms of action, and monitor the relevant biomarkers when combining compounds in the same class. As always, consult a licensed healthcare provider before making any decisions about combining research compounds.
This platform provides informational tools only, not medical advice. This comparison is for educational purposes only. Consult a licensed provider.
Dose Range
Route
Frequency
Dosing Notes
Side Effects
Contraindications
Lab Testing
Disclosed Labs